U.S. Banks Stock News

NYSE:ADT
NYSE:ADTConsumer Services

ADT Bets On Camera Free AI Sensing And Verisure Partnership Potential

ADT (NYSE:ADT) has acquired Origin AI, a company focused on camera free AI presence sensing technology. The deal includes Origin AI's patent portfolio and will be integrated into ADT's smart home security platform. ADT has also signed a long term commercial agreement with Verisure to bring this AI sensing technology to Europe and Latin America. For investors watching NYSE:ADT at a share price of $8.11, this move signals a push to differentiate its smart home offering with AI driven presence...
NasdaqGS:TWFG
NasdaqGS:TWFGInsurance

TWFG (TWFG) Net Margin Recovery Tests Bullish Long Term Earnings Narrative

TWFG (TWFG) has just posted its FY 2025 numbers, with Q4 revenue at US$68.8 million and basic EPS of US$0.18. This caps off a trailing twelve month profile that includes revenue of US$247.1 million and basic EPS of US$0.51 alongside reported earnings growth of 179.5% over the past year. The company has seen revenue rise from US$49.5 million in Q4 2024 to US$68.8 million in Q4 2025, while quarterly EPS has moved from US$0.11 to US$0.18. This sets the backdrop for analyst forecasts that point...
NYSE:AMBP
NYSE:AMBPPackaging

Ardagh Metal Packaging (AMBP) Margins Stay Fragile As Profit Swings Challenge Bullish Earnings Narratives

Ardagh Metal Packaging (NYSE:AMBP) has wrapped up FY 2025 with fourth quarter revenue of US$1.3b and a basic EPS loss of US$0.03, alongside net income excluding extra items of a US$16m loss. Over recent periods the company has seen revenue move from US$1.2b in Q4 2024 to US$1.3b in Q4 2025, with quarterly EPS ranging between a loss of US$0.03 and a profit of roughly US$0.04, while trailing twelve month net income excluding extra items sits at US$11m on US$5.5b of revenue. With the company now...
NasdaqCM:IKT
NasdaqCM:IKTBiotechs

A Look At Inhibikase Therapeutics (IKT) Valuation After New FDA Designations And Phase 2a Trial Progress

Inhibikase Therapeutics (IKT) has moved into focus after fresh FDA designations and progress in its Phase 2a trial for IkT-148009 targeting Parkinson’s disease, even as ongoing financial instability remains part of the picture. See our latest analysis for Inhibikase Therapeutics. The recent FDA designations and Phase 2a progress appear to be feeding into momentum, with a 7 day share price return of 20.11% and a 90 day share price return of 37.50%, even though the 1 year total shareholder...
NasdaqCM:EOSE
NasdaqCM:EOSEElectrical

Eos Energy Enterprises (EOSE) Swings To US$1.3b Q4 Profit Challenging Loss-Focused Narratives

Eos Energy Enterprises (EOSE) just released its FY 2025 numbers with Q4 revenue at US$58.0 million and basic EPS of US$4.19, while the latest trailing twelve month figures show revenue of US$114.2 million and a basic EPS loss of US$0.75. The company has seen quarterly revenue move from US$7.3 million and a basic EPS loss of US$2.20 in Q4 2024 to US$58.0 million and basic EPS of US$4.19 in Q4 2025, with trailing twelve month net income at a US$194.5 million loss. These figures are shaping how...
NYSE:VSXY
NYSE:VSXYSpecialty Retail

Is It Too Late To Consider Victoria's Secret (VSCO) After Its 1-Year Share Price Surge?

If you are wondering whether Victoria's Secret shares still offer value after a strong run, the key is to look past the headlines and focus on what the current price really implies. The stock most recently closed at US$65.75, with returns of 7.2% over 7 days, 17.6% over 30 days, 23.2% year to date, 144.7% over 1 year and 74.2% over 3 years. Recent attention around Victoria's Secret has centered on its position in the US retail space and how investors view its brand and store footprint. This...
NYSE:GBCI
NYSE:GBCIBanks

Glacier Bancorp (GBCI) Earnings Growth Reinforces Bullish Narratives Despite Premium P/E Concerns

Glacier Bancorp (GBCI) just closed FY 2025 with fourth quarter revenue of US$266.9 million and basic EPS of US$0.49, alongside full year trailing twelve month revenue of US$952.7 million and EPS of US$2.00 that reflected 25.7% earnings growth over the past year. Over recent periods, revenue has moved from US$802.5 million to US$952.7 million on a trailing twelve month basis, while EPS has gone from US$1.68 to US$2.00. This sets up a story that now centers on how sustainable those margins and...
NYSE:KGS
NYSE:KGSEnergy Services

Kodiak Gas Services (KGS) Earnings Growth And 6.2% Margin Test Recurring Revenue Narrative

Kodiak Gas Services (KGS) has just wrapped up FY 2025 with Q4 revenue of US$332.9 million and basic EPS of US$0.29, alongside trailing twelve month revenue of US$1.3 billion and EPS of US$0.92 that sit against a 61.4% earnings growth figure for the year. The company has seen revenue move from US$1.2 billion and EPS of US$0.60 on a trailing basis at the end of 2024 to the latest US$1.3 billion and US$0.92, with net profit margin at 6.2% compared with 4.3% the prior year. This puts the focus...
NYSE:DEA
NYSE:DEAOffice REITs

Easterly Government Properties Virginia Deal And What It Means For Valuation

Easterly Government Properties (NYSE:DEA) has completed a $44.5 million acquisition of a three asset portfolio in Virginia. The properties are described as mission critical government facilities with long term leases. The transaction was completed at a high cash cap rate and is characterized by the company as immediately accretive. For investors watching NYSE:DEA, this deal adds fresh context to a stock that is trading at $23.56 and has returned 10.6% year to date, despite a 9.0% decline...
NYSE:SJM
NYSE:SJMFood

Smucker (SJM) Quarterly Loss Of US$724 Million Tests Bullish Margin Recovery Narrative

J. M. Smucker (SJM) has just posted Q3 2026 results with revenue of US$2.3 billion and a basic EPS loss of US$6.79, as net income excluding extra items came in at a loss of US$724.2 million. Over recent quarters the company has seen revenue move from US$2.1 billion in Q2 2025 to US$2.3 billion in Q3 2026, while basic EPS has swung between a loss of US$6.85 in Q4 2025 and a profit of US$2.26 in Q2 2026 before returning to a loss in the latest period. This sets up a results season in which...
NasdaqGS:AMSF
NasdaqGS:AMSFInsurance

AMERISAFE (AMSF) Margin Compression Challenges Long‑Held Earnings Stability Narrative

AMERISAFE (AMSF) has wrapped up FY 2025 with fourth quarter total revenue of US$81.6 million and basic EPS of US$0.55, alongside net income of US$10.4 million, putting a clear spotlight on how its workers’ compensation book is translating into bottom line results. The company has seen trailing twelve month revenue sit at US$317.3 million with EPS of US$2.48 and net income of US$47.1 million, giving investors a fuller view of how the latest quarter fits into the broader earnings trend. With...
NasdaqGS:TCOM
NasdaqGS:TCOMHospitality

Trip.com Group (NasdaqGS:TCOM) TTM 53.3% Net Margin Challenges Bearish Profit Durability Narratives

Trip.com Group (NasdaqGS:TCOM) closed out FY 2025 with fourth quarter revenue of C¥15.4b and basic EPS of C¥6.53, while trailing twelve month figures showed revenue of C¥62.4b and EPS of C¥50.62, anchoring the latest print against a much stronger full year base. Over the past few quarters, the company has seen revenue move from C¥14.8b in Q2 2025 and C¥18.3b in Q3 2025 to C¥15.4b in Q4 2025. Quarterly EPS ranged from C¥6.48 in Q1 2025 to C¥30.36 in Q3 2025 and C¥6.53 in Q4 2025, giving...
NYSE:ZVIA
NYSE:ZVIABeverage

Zevia (ZVIA) Losses Shrink Sharply Challenging Bearish Profitability Narratives

Zevia PBC (ZVIA) just wrapped up FY 2025 with Q4 revenue of US$37.9 million and a basic EPS loss of US$0.02, alongside a trailing twelve month loss of US$9.9 million on revenue of US$161.3 million. Over recent quarters, the company has seen quarterly revenue move between US$36.4 million and US$44.5 million, while basic EPS losses have ranged from US$0.01 to US$0.10 per share. Together, these figures present a picture of relatively steady sales but still negative earnings. For investors, the...
NasdaqGS:OPCH
NasdaqGS:OPCHHealthcare

Option Care Health Growth Story Faces Debt And Biosimilar Pressures

Option Care Health reported strong 2025 results, with significant revenue growth and expanded service offerings across its infusion network. The company increased its footprint of infusion suites and invested in automation and AI to support operational efficiency. Management highlighted disciplined capital allocation, including targeted M&A, while managing headwinds from biosimilar conversions and reimbursement pressures. Option Care Health (NasdaqGS:OPCH) is coming off a year of solid...
NYSE:AI
NYSE:AISoftware

C3.ai (AI) Q3 Loss Worsening To US$0.94 EPS Reinforces Bearish Profitability Concerns

C3.ai (AI) just posted its Q3 2026 numbers, with revenue of US$53.3 million and a basic EPS loss of US$0.94, while trailing twelve month revenue came in at US$307.4 million and EPS at a loss of US$3.17. Over the last six reported quarters, the company has seen quarterly revenue move from US$94.3 million in Q2 2025 to US$53.3 million in Q3 2026, with basic EPS losses ranging between US$0.52 and US$0.94. This sets up an earnings story that is centered on loss-making margins and the pace at...
NasdaqGS:SFNC
NasdaqGS:SFNCBanks

Simmons First National (SFNC) Net Interest Margin Rebound Tests Bearish Profitability Narratives

Simmons First National (SFNC) closed out FY 2025 with fourth quarter revenue of US$233.9 million and basic EPS of US$0.54, following a turbulent year in which trailing twelve month figures show revenue of US$37.4 million and a basic EPS loss of US$2.96. Over recent quarters, the company has seen quarterly revenue move from US$162.7 million in Q3 2024 to US$195.2 million in Q4 2024, then to US$182.8 million, US$202.2 million and US$233.9 million through Q1 to Q4 2025. Basic EPS shifted from...
NasdaqGS:SRPT
NasdaqGS:SRPTBiotechs

Sarepta Therapeutics (SRPT) Q4 Loss Deepens And Tests Bullish Profitability Narrative

Sarepta Therapeutics (SRPT) closed out FY 2025 with Q4 revenue of US$442.9 million and a basic EPS loss of US$3.93, alongside a full year trailing net loss of US$713.4 million on US$2.2 billion of revenue. Over the last six quarters in the data, revenue has ranged from US$399.4 million to US$744.9 million per quarter. Basic EPS has swung between a profit of US$2.01 and a loss of US$4.60, highlighting sharp shifts in margins that keep profitability firmly in focus for investors. See our full...
NYSE:AUB
NYSE:AUBBanks

Atlantic Union Bankshares CFO Transition And What It May Mean For Valuation

Atlantic Union Bankshares (NYSE:AUB) has appointed Alexander D. Dodd as Chief Financial Officer. Dodd succeeds longtime CFO Robert M. Gorman, who served in the role for nearly 14 years. The company is planning a structured transition that includes an advisory period for Gorman. For investors watching Atlantic Union Bankshares at a share price of $39.51, a CFO transition of this kind is a meaningful leadership event. With Robert M. Gorman stepping aside after nearly 14 years and Alexander D...
NasdaqGM:RUM
NasdaqGM:RUMInteractive Media and Services

Rumble Shorts Google Play Launch Tests Short Video Growth Potential

Rumble Shorts has been approved on Google Play, bringing the company’s short form video product to Android users. The launch broadens access to Rumble’s content platform and extends its presence within a major mobile ecosystem. For investors watching NasdaqGM:RUM, the rollout of Rumble Shorts on Google Play adds a new layer to the company’s product mix at a time when short form video remains a core format for online viewing. Shares most recently closed at $5.76, with the stock showing a 1...
NYSE:AEE
NYSE:AEEIntegrated Utilities

Ameren Missouri Bond Sale Reshapes Debt Profile And Funds Grid Investment

Ameren Missouri, a subsidiary of Ameren Corporation, has priced a new public offering of first mortgage bonds. The company plans to use the proceeds to refinance existing debt and fund near term capital expenditures. This financing step is intended to reshape Ameren Missouri's debt profile and support upcoming investment needs. For investors watching Ameren (NYSE: AEE), this bond move sits alongside a share price of $111.44 and multi year returns. The stock is up 2.9% over the past week,...
NYSE:TROX
NYSE:TROXChemicals

Tronox Weighs Rare Earth Expansion And New Funding Options Amid Losses

Tronox Holdings (NYSE:TROX) is expanding further into the rare earth supply chain, signaling a push beyond its traditional titanium dioxide business. The company has filed a universal shelf registration, giving it flexibility to raise capital through a range of securities if and when it chooses. At a share price of $7.2, NYSE:TROX has had a mixed return profile, with a 68.6% gain year to date alongside a 46.9% decline over 3 years and a 52.5% decline over 5 years. Over the past month the...
NasdaqGS:BOOM
NasdaqGS:BOOMEnergy Services

DMC Global (BOOM) Is Down 25.3% After Wider Q4 Loss And Soft 2026 Outlook Has The Bull Case Changed?

DMC Global Inc. has reported its fourth-quarter 2025 results, with sales falling to US$143.53 million from US$152.37 million a year earlier and swinging from a small net income to a net loss of US$11.16 million. For full-year 2025, the company reduced its net loss to US$13.45 million despite lower sales of US$609.84 million, but management’s first-quarter 2026 guidance flags continued operational pressures and weather-related disruptions that are expected to weigh on near-term...
NasdaqGS:INTA
NasdaqGS:INTASoftware

Is It Time To Reconsider Intapp (INTA) After A 67% Share Price Slide

If you are wondering whether Intapp is starting to look interesting at its current share price, you are not alone and this article is designed to help you weigh that up. The stock has recently seen a 5.2% decline over the last week, a 44.9% decline over the last month and a 67.3% decline over the past year, which will naturally raise questions about both risk and potential future returns. These moves sit against a backdrop of ongoing coverage of Intapp as a listed software company, with...